🇺🇸 FDA
Pipeline program

Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

DEN-204

Phase 2 mab completed

Quick answer

Takeda's Tetravalent Dengue Vaccine Candidate (TDV) for Dengue Fever is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Dengue Fever
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials